Do chronic myeloid leukemia patients with late "warning" responses benefit from "watch and wait" or switching therapy to a second generation tyrosine kinase inhibitor?
Identifiers
Identifiers
Services
Services
Date issued
2014Journal title
AMERICAN JOURNAL OF HEMATOLOGY
Type of content
Artigo
